Patents by Inventor Mark D. Cochran

Mark D. Cochran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8071738
    Abstract: The present invention provides isolated and purified DNA encoding feline CD80 (B7-1) ligand, feline CD86 (B7-2) ligand, feline CD28 receptor, or feline CTLA-4 (CD152) receptor, as well as vectors comprising nucleic acid encoding feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a host cells transformed with CD80-encoding vectors, CD86-encoding vectors, CD28-encoding vectors, or CTLA-4-encoding vectors. The invention provides polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a vaccine comprising an effective amount of polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention also provides vaccines which further comprise immunogens derived from pathogens. The invention provides for vaccines capable of enhancing an immune response. The invention also provides for vaccines capable of suppressing and immune response.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: December 6, 2011
    Assignees: Texas A&M University System, Intervet Inc.
    Inventors: Ellen W. Collisson, In-Soo Choi, Barbara J. Winslow, Mark D. Cochran
  • Patent number: 7972604
    Abstract: The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.
    Type: Grant
    Filed: August 27, 2010
    Date of Patent: July 5, 2011
    Assignee: Intervet Inc.
    Inventors: Mark D. Cochran, Gary R. Peterson, Stephen V. Lair, Richard M. Synenki
  • Patent number: 7892564
    Abstract: The present invention provides a recombinant, attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene. This attenuated virus is useful as a vaccine against infectious laryngotracheitis virus. The present invention also provides a recombinant, attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the US2 gene, UL47-like gene, ORF4 gene or glycoprotein g60 gene. The present invention also provides a method for distinguishing chickens or other poultry vaccinated with a recombinant infectious laryngotracheitis virus which produces no glycoprotein gG from those infected with a naturally-occurring infectious laryngotracheitis virus.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: February 22, 2011
    Assignee: Schering-Plough Animal Health Corp.
    Inventors: Martha A. Wild, Mark D. Cochran
  • Patent number: 7892561
    Abstract: The invention provides new, specific antigenic peptides from the protein GDF8. The invention also provides fusion proteins comprising the new peptides, immunogens and vaccines based on the new peptides and/or fusion proteins, antibodies that specifically bind to the new peptides of GDF8, and methods of treating animals in order to modulate the activity of GDF8, employing vaccines or antibodies according to the invention.
    Type: Grant
    Filed: August 4, 2009
    Date of Patent: February 22, 2011
    Assignee: Schering-Plough Animal Health Corporation
    Inventors: David E. Junker, Mark D. Cochran
  • Publication number: 20110008377
    Abstract: The present invention provides isolated and purified DNA encoding feline CD80 (B7-1) ligand, feline CD86 (B7-2) ligand, feline CD28 receptor, or feline CTLA-4 (CD152) receptor, as well as vectors comprising nucleic acid encoding feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a host cells transformed with CD80-encoding vectors, CD86-encoding vectors, CD28-encoding vectors, or CTLA-4-encoding vectors. The invention provides polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a vaccine comprising an effective amount of polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention also provides vaccines which further comprise immunogens derived from pathogens. The invention provides for vaccines capable of enhancing an immune response. The invention also provides for vaccines capable of suppressing and immune response.
    Type: Application
    Filed: June 4, 2010
    Publication date: January 13, 2011
    Inventors: Ellen W. Collisson, Insoo Choi, Barbara J. Winslow, Mark D. Cochran
  • Publication number: 20110008389
    Abstract: The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.
    Type: Application
    Filed: August 27, 2010
    Publication date: January 13, 2011
    Applicant: INTERVET INC.
    Inventors: MARK D. COCHRAN, GARY R. PETERSON, STEPHEN V. LAIR, RICHARD M. SYNENKI
  • Patent number: 7807456
    Abstract: The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.
    Type: Grant
    Filed: December 17, 2009
    Date of Patent: October 5, 2010
    Assignee: Intervet Inc.
    Inventors: Mark D. Cochran, Gary R. Petersen, Stephen V. Lair, Richard M. Synenki
  • Publication number: 20100166800
    Abstract: The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.
    Type: Application
    Filed: December 17, 2009
    Publication date: July 1, 2010
    Inventors: Mark D. Cochran, Gary R. Petersen, Stephen V. Lair, Richard M. Synenki
  • Patent number: 7745593
    Abstract: The present invention provides isolated and purified DNA encoding feline CD80 (B7-1) ligand, feline CD86 (B7-2) ligand, feline CD28 receptor, or feline CTLA-4 (CD152) receptor, as well as vectors comprising nucleic acid encoding feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a host cells transformed with CD80-encoding vectors, CD86-encoding vectors, CD28-encoding vectors, or CTLA-4-encoding vectors. The invention provides polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention provides a vaccine comprising an effective amount of polypeptides encoded by the nucleic acid of feline CD80, feline CD86, feline CD28, or feline CTLA-4. The present invention also provides vaccines which further comprise immunogens derived from pathogens. The invention provides for vaccines capable of enhancing an immune response. The invention also provides for vaccines capable of suppressing and immune response.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: June 29, 2010
    Assignees: Texas A&M University System, Intervet Inc.
    Inventors: Ellen W. Collisson, Insoo Choi, Barbara J. Winslow, Mark D. Cochran
  • Patent number: 7732187
    Abstract: The present invention discloses attenuated Clostridium perfringens organisms that express a substantially nontoxic alpha-toxin. The expressed alpha-toxin is a deletion mutein that relative to the alpha-toxin of the mature alpha-toxin of Clostridium perfringens strain 13, is missing at least nine consecutive amino acid residues including His68. The present invention also discloses attenuated organisms that encode the muteins, as well as the use of such attenuated organisms as vaccines.
    Type: Grant
    Filed: April 12, 2007
    Date of Patent: June 8, 2010
    Assignee: Intervet Inc.
    Inventors: Mark D. Cochran, Gary R. Petersen, Stephen V. Lair, Richard M. Synenki
  • Publication number: 20100008948
    Abstract: The present invention provides a novel avian herpesvirus (NAHV) vector and recombinant vaccines made therefrom that are useful to immunize avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease. Methods of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease are also provided.
    Type: Application
    Filed: August 11, 2009
    Publication date: January 14, 2010
    Inventors: Mark D. Cochran, Stephanie M. Cook, Matha A. Wild
  • Publication number: 20090311282
    Abstract: The invention provides new, specific antigenic peptides from the protein GDF8. The invention also provides fusion proteins comprising the new peptides, immunogens and vaccines based on the new peptides and/or fusion proteins, antibodies that specifically bind to the new peptides of GDF8, and methods of treating animals in order to modulate the activity of GDF8, employing vaccines or antibodies according to the invention.
    Type: Application
    Filed: August 4, 2009
    Publication date: December 17, 2009
    Inventors: DAVID E. JUNKER, MARK D. COCHRAN
  • Publication number: 20090274724
    Abstract: The present invention provides novel viral vectors. In one embodiment, the present invention provides mutant and recombinant bovine adenoviruses having a deletion and/or insertion of DNA in the early gene region 4 (E4). In another embodiment, the present invention provides mutant and recombinant bovine adenovirus 1 viruses having a deletion and/or insertion of DNA in the early gene region 3 (E3). The present invention also contemplates the use of the viral vectors for vaccination, gene therapy or other applications as suitable.
    Type: Application
    Filed: June 23, 2009
    Publication date: November 5, 2009
    Inventors: Christina H. Chiang, Mark D. Cochran
  • Patent number: 7585648
    Abstract: The invention provides new, specific nucleic acids encoding antigenic peptides from the protein GDF8. The invention also provides nucleic acids encoding fusion proteins comprising the new peptides, immunogens and vaccines based on the nucleic acids encoding new peptides and/or fusion proteins, antibodies that specifically bind to the new peptides of GDF8, and methods of treating animals in order to modulate the activity of GDF8, employing vaccines or antibodies according to the invention.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: September 8, 2009
    Assignee: Schering-Plough Animal Health Corporation
    Inventors: David E. Junker, Mark D. Cochran
  • Publication number: 20090208522
    Abstract: The invention provides a fusion protein comprising a plant virus coat protein and a GDF8 peptide domain, or antigenic fragment of the GDF8 peptide domain. Plant virus vectors expressing the fusion protein and methods of using these vectors are also provided.
    Type: Application
    Filed: August 22, 2008
    Publication date: August 20, 2009
    Inventors: David E. Junker, Mark D. Cochran, Mark L. Smith, Kenneth E. Palmer, Gregory P. Pogue
  • Publication number: 20090191239
    Abstract: The present invention provides a recombinant, attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene. This attenuated virus is useful as a vaccine against infectious laryngotracheitis virus. The present invention also provides a recombinant, attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the US2 gene, UL47-like gene, ORF4 gene or glycoprotein g60 gene. The present invention also provides a method for distinguishing chickens or other poultry vaccinated with a recombinant infectious laryngotracheitis virus which produces no glycoprotein gG from those infected with a naturally-occurring infectious laryngotracheitis virus.
    Type: Application
    Filed: January 30, 2009
    Publication date: July 30, 2009
    Inventors: Martha A. Wild, Mark D. Cochran
  • Patent number: 7501491
    Abstract: The present invention provides a recombinant, attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene. This attenuated virus is useful as a vaccine against infectious laryngotracheitis virus. The present invention also provides a recombinant, attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the US2 gene, UL47-like gene, ORF4 gene or glycoprotein g60 gene. The present invention also provides a method for distinguishing chickens or other poultry vaccinated with a recombinant infectious laryngotracheitis virus which produces no glycoprotein gG from those infected with a naturally-occurring infectious laryngotracheitis virus.
    Type: Grant
    Filed: March 13, 2008
    Date of Patent: March 10, 2009
    Assignee: Schering-Plough Animal Health Corp.
    Inventors: Martha A. Wild, Mark D. Cochran
  • Patent number: 7432079
    Abstract: The invention provides a fusion protein comprising a plant virus coat protein and a GDF8 peptide domain, or antigenic fragment of the GDF8 peptide domain. Plant virus vectors expressing the fusion protein and methods of using these vectors are also provided.
    Type: Grant
    Filed: December 21, 2005
    Date of Patent: October 7, 2008
    Assignee: Schering-Plough Animal Health Corporation
    Inventors: David E. Junker, Mark D. Cochran, Mark L. Smith, Kenneth E. Palmer, Gregory P. Pogue
  • Publication number: 20080227156
    Abstract: The invention provides new, specific antigenic peptides from the protein GDF8. The invention also provides fusion proteins comprising the new peptides, immunogens and vaccines based on the new peptides and/or fusion proteins, antibodies that specifically bind to the new peptides of GDF8, and methods of treating animals in order to modulate the activity of GDF8, employing vaccines or antibodies according to the invention.
    Type: Application
    Filed: April 2, 2008
    Publication date: September 18, 2008
    Inventors: David E. Junker, Mark D. Cochran
  • Publication number: 20080175859
    Abstract: The present invention provides a recombinant, attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the glycoprotein gG gene. This attenuated virus is useful as a vaccine against infectious laryngotracheitis virus. The present invention also provides a recombinant, attenuated infectious laryngotracheitis virus comprising the infectious laryngotracheitis viral genome which contains a deletion in the US2 gene, UL47-like gene, ORF4 gene or glycoprotein g60 gene. The present invention also provides a method for distinguishing chickens or other poultry vaccinated with a recombinant infectious laryngotracheitis virus which produces no glycoprotein gG from those infected with a naturally-occurring infectious laryngotracheitis virus.
    Type: Application
    Filed: March 13, 2008
    Publication date: July 24, 2008
    Inventors: Martha A. Wild, Mark D. Cochran